Clinical significance of Wip1 overexpression and its association with the p38MAPK/p53/p16 pathway in NSCLC

Yang,Shize; Dong,Siyuan; Qu,Xiaohan; Zhong,Xinwen; Zhang,Qigang

doi:10.3892/mmr.2016.6032

Clinical significance of Wip1 overexpression and its association with the p38MAPK/p53/p16 pathway in NSCLC

Authors:
- Shize Yang
- Siyuan Dong
- Xiaohan Qu
- Xinwen Zhong
- Qigang Zhang
View Affiliations

Affiliations: Department of Thoracic Surgery, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning 110000, P.R. China
Published online on: December 13, 2016 https://doi.org/10.3892/mmr.2016.6032
Pages: 719-723
Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Wip1 is deregulated in numerous human malignancies. However, its roles in non‑small cell lung cancer (NSCLC) remain unclear. In the current study, the expression of Wip1 was investigated in NSCLC and its clinical significance was detected. Immunohistochemical staining was used to measure the expression of (wild‑type p53 induced phosphatase 1) Wip1, p38 mitogen‑activated protein kinase (MAPK), p53, p16 protein in a group of 60 NSCLC and 20 normal lung tissues. In addition, western blotting was performed to detect the Wip1 protein in fresh tissues. The correlations between clinical characteristics and Wip1 expression were analyzed using SPSS, version 16.0 software. The expression of Wip1 was positive in 63.3% (38/60) of NSCLC tissues, and in none of the normal lung tissues (0/20; P<0.01). In addition, Wip1 overexpression was significantly associated with tumor length and differentiation (P=0.008 and 0.03, respectively). The expression of Wip1 was negatively correlated with that of p38MAPK, p53 and p16 (r=‑0.284, ‑0.352 and ‑0.348, respectively). The results of the current study demonstrated that Wip1 was frequently overexpressed in NSCLC, which may serve an essential role in the p38MAPK/p53/p16 signaling pathway.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
2	Fiscella M, Zhang H, Fan S, Sakaguchi K, Shen S, Mercer WE, Van De Woude GF, O'Connor PM and Appella E: Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner. Proc Natl Acad Sci USA. 94:6048–6053. 1997. View Article : Google Scholar : PubMed/NCBI
3	Buss MC, Remke M, Lee J, Gandhi K, Schniederjan MJ, Kool M, Northcott PA, Pfister SM, Taylor MD and Castellino RC: The WIP1 oncogene promotes progression and invasion of aggressive medulloblastoma variants. Oncogene. 34:1126–1140. 2015. View Article : Google Scholar : PubMed/NCBI
4	Liu S, Qi L, Han W, Wan X, Jiang S, Li Y, Xie Y, Liu L, Zeng F, Liu Z and Zu X: Overexpression of wip1 is associated with biologic behavior in human clear cell renal cell carcinoma. PLoS One. 9:e1102182014. View Article : Google Scholar : PubMed/NCBI
5	Li ZT, Zhang L, Gao XZ, Jiang XH and Sun LQ: Expression and significance of the Wip1 proto-oncogene in colorectal cancer. Asian Pac J Cancer Prev. 14:1975–1979. 2013. View Article : Google Scholar : PubMed/NCBI
6	Ruark E, Snape K, Humburg P, Loveday C, Bajrami I, Brough R, Rodrigues DN, Renwick A, Seal S, Ramsay E, et al: Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer. Nature. 493:406–410. 2013. View Article : Google Scholar : PubMed/NCBI
7	Bulavin DV, Demidov ON, Saito S, Kauraniemi P, Phillips C, Amundson SA, Ambrosino C, Sauter G, Nebreda AR, Anderson CW, et al: Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat Genet. 31:210–215. 2002. View Article : Google Scholar : PubMed/NCBI
8	Dudgeon C, Shreeram S, Tanoue K, Mazur SJ, Sayadi A, Robinson RC, Appella E and Bulavin DV: Genetic variants and mutations of PPM1D control the response to DNA damage. Cell Cycle. 12:2656–2664. 2013. View Article : Google Scholar : PubMed/NCBI
9	Filipponi D, Muller J, Emelyanov A and Bulavin DV: Wip1 controls global heterochromatin silencing via ATM/BRCA1-dependent DNA methylation. Cancer Cell. 24:528–541. 2013. View Article : Google Scholar : PubMed/NCBI
10	Casanovas O, Miró F, Estanyol JM, Itarte E, Agell N and Bachs O: Osmotic stress regulates the stability of cyclin D1 in a p38SAPK2-dependent manner. J Biol Chem. 275:35091–35097. 2000. View Article : Google Scholar : PubMed/NCBI
11	Lee JS, Lee MO, Moon BH, Shim SH, Fornace AJ Jr and Cha HJ: Senescent growth arrest in mesenchymal stem cells is bypassed by Wip1-mediated downregulation of intrinsic stress signaling pathways. Stem Cells. 27:1963–1975. 2009. View Article : Google Scholar : PubMed/NCBI
12	Liao Q, Guo X, Li X, Xiong W, Li X, Yang J, Chen P, Zhang W, Yu H, Tang H, et al: Prohibitin is an important biomarker for nasopharyngeal carcinoma progression and prognosis. Eur J Cancer Prev. 22:68–76. 2013. View Article : Google Scholar : PubMed/NCBI
13	Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V and Sobin L: Internation Association for the Study of Lung Cancer: The IASLC Lung Cancer Staging Project: Proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2:706–714. 2007. View Article : Google Scholar : PubMed/NCBI
14	Koom WS, Park SY, Kim W, Kim M, Kim JS, Kim H, Choi IK, Yun CO and Seong J: Combination of radiotherapy and adenovirus-mediated p53 gene therapy for MDM2-overexpressing hepatocellular carcinoma. J Radiat Res. 53:202–210. 2012. View Article : Google Scholar : PubMed/NCBI
15	Saito-Ohara F, Imoto I, Inoue J, Hosoi H, Nakagawara A, Sugimoto T and Inazawa J: PPM1D is a potential target for 17q gain in neuroblastoma. Cancer Res. 63:1876–1883. 2003.PubMed/NCBI
16	Yang DH, He JA, Li J, Ma WF, Hu XH, Xin SJ and Duan ZQ: Expression of proto-oncogene Wip1 in breast cancer and its clinical significance. Zhonghua Yi Xue Za Zhi. 90:519–522. 2010.(In Chinese). PubMed/NCBI
17	Sculier JP: Nonsmall cell lung cancer. Eur Respir Rev. 22:33–36. 2013. View Article : Google Scholar : PubMed/NCBI
18	Tarulli GA, De Silva D, Ho V, Kunasegaran K, Ghosh K, Tan BC, Bulavin DV and Pietersen AM: Hormone-sensing cells require Wip1 for paracrine stimulation in normal and premalignant mammary epithelium. Breast Cancer Res. 15:R102013. View Article : Google Scholar : PubMed/NCBI
19	Xu H, Liu C, Zhao Z, Gao N, Chen G, Wang Y and Cui J: Clinical implications of GRHL3 protein expression in breast cancer. Tumour Biol. 35:1827–1831. 2014. View Article : Google Scholar : PubMed/NCBI
20	Yang D, Zhang H, Hu X, Xin S and Duan Z: Abnormality of pl6/p38MAPK/p53/Wipl pathway in papillary thyroid cancer. Gland Surg. 1:33–38. 2012.PubMed/NCBI
21	Bulavin DV, Phillips C, Nannenga B, Timofeev O, Donehower LA, Anderson CW, Appella E and Fornace AJ Jr: Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16 (Ink4a)-p19 (Arf) pathway. Nat Genet. 36:343–350. 2004. View Article : Google Scholar : PubMed/NCBI